Targeting the MDM2-p53 protein–protein interaction for new cancer therapeutics
The DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“as Nutlin compounds have a 100-fold greater affinity for MDM2 over MDM4 [13].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [13]
In the citing paper
“However, as suggested [13], p53 induced up-regulation of MDM2 might promote MDM4 degradation in some cell lines, which, in turn, would activate apoptosis cascade.”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [13]
Citations
Cites
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763 · cited 2×
“Computational docking was performed using the GOLD program [43, 44] to dock each hit to the p53-binding site in MDM2.”
MethodIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Live or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192 · cited 1×
“An efficient synthetic method featuring a [1,3]-dipolar cycloaddition reaction as the key step was developed for the synthesis of the designed compound.”
MethodMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · cited 1×
“MDM2 is an oncoprotein that was initially discovered by its overexpression in a spontaneously transformed mouse cell line [8–12].”
BackgroundImproved protein–ligand docking using GOLD
Verdonk, M. L., Cole, J. C., Hartshorn, M. J., Murray, C. W., & Taylor, R. D. (2003) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10465 · Cited by 3,067 · cited 2×
“Computational docking was performed using the GOLD program [43, 44] to dock each hit to the p53-binding site in MDM2.”
Methodp53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864 · cited 1×
“apoptosis [71, 72].”
T antigen is bound to a host protein in SY40-transformed cells
LANE, D. P., & CRAWFORD, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,394
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949 · cited 1×
“For example, overexpression of MDM2 provides cells a growth advantage, promotes tumorigenesis, and correlates with a worse clinical prognosis and poor response to cancer therapy [18–24].”
BackgroundLinzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,813
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801 · cited 1×
“In turn, MDM2 protein directly binds to p53 and inhibits the activity of p53 through multiple mechanisms: MDM2 (1) directly inhibits the transactivation function of p53, (2) exports p53 out of the nucleus, and (3) promotes proteosome-mediated degradation of p53 through its E3 ubiquitin ligase activity [13–15].”
BackgroundEldridge, M. D., Murray, C. W., Auton, T. R., Paolini, G. V., & Mee, R. P. (1997) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1007996124545 · Cited by 1,686 · cited 1×
“Their binding affinities were ranked using Chemscore [45] and X-score [46], and the top 200 ranked compounds from each scoring function were combined, yielding 354 non-redundant compounds.”
MethodRescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · cited 1×
“The physiological relevance of this regulatory loop was demonstrated by the genetic evidence that embryonic lethality of Mdm2-null mice can be successfully rescued by the simultaneous deletion of the p53 gene [16, 17].”
BackgroundFridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280 · cited 1×
“The physiological relevance of this regulatory loop was demonstrated by the genetic evidence that embryonic lethality of Mdm2-null mice can be successfully rescued by the simultaneous deletion of the p53 gene [16, 17].”
BackgroundBond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265 · cited 2×
“For example, overexpression of MDM2 provides cells a growth advantage, promotes tumorigenesis, and correlates with a worse clinical prognosis and poor response to cancer therapy [18–24].”
BackgroundWang, R., Lai, L., & Wang, S. (2002) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1016357811882 · Cited by 1,191 · cited 1×
“Their binding affinities were ranked using Chemscore [45] and X-score [46], and the top 200 ranked compounds from each scoring function were combined, yielding 354 non-redundant compounds.”
MethodSelf-citationp53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986 · cited 1×
“MDM2 is an oncoprotein that was initially discovered by its overexpression in a spontaneously transformed mouse cell line [8–12].”
BackgroundThe MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982 · cited 2×
“Furthermore, MDM2 amplification and p53 mutation are essentially mutually exclusive [22].”
BackgroundDeLeo, A. B., Jay, G., Appella, E., Dubois, G. C., Law, L. W., & Old, L. J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.5.2420 · Cited by 721 · cited 1×
“The p53 protein was identified in 1979 [4–6], and its gene, called TP53, was cloned in 1983 [7].”
BackgroundSmall-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708 · cited 5×
“In some but not all tumor cells, activation of p53 by MDM2 inhibitors induces both cell cycle arrest and cell death [33, 50, 65].”
BackgroundInfluentialFakharzadeh, S. S., Trusko, S. P., & George, D. L. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb07676.x · Cited by 704 · cited 1×
“MDM2 is an oncoprotein that was initially discovered by its overexpression in a spontaneously transformed mouse cell line [8–12].”
BackgroundDing, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., Stuckey, J., Krajewski, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051122a · Cited by 702
Self-citationMapping of the p53 and mdm-2 interaction domains.
Chen, J., Marechal, V, & Levine, A. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.7.4107 · Cited by 689 · cited 1×
“The MDM2-p53 interaction was mapped to the first ~120 amino acid residues at the N-terminus of MDM2 and to the N-terminus of the transactivation domain of p53 [29, 30].”
BackgroundShangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660 · cited 16×
“In some but not all tumor cells, activation of p53 by MDM2 inhibitors induces both cell cycle arrest and cell death [33, 50, 65].”
BackgroundInfluentialSelf-citationStructure-based design of potent non-peptide MDM2 inhibitors
Ding, K., Lu, Y., Nikolovska-Coleska, Z., Qiu, S., Ding, Y., Gao, W., Stuckey, J., Krajewski, K., Roller, P. P., Tomita, Y., et al. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051147z · Cited by 657 · cited 6×
“To date, at least three compounds have been advanced into early clinical development, including two compounds from Roche and one compound from the University of Michigan.”
MethodInfluentialSelf-citationMDM2 — master regulator of the p53 tumor suppressor protein
Momand, J., Wu, H.-H., & Dasgupta, G. (2000) · Gene · doi:10.1016/s0378-1119(99)00487-4 · Cited by 641 · cited 1×
“amplification of the MDM2 gene, single nucleotide polymorphism at nucleotide 309 (SNP309) in its gene promoter, enhanced transcription, and increased translation account for MDM2 overproduction [18, 24–26].”
BackgroundChalcones: An Update on Cytotoxic and Chemoprotective Properties
Go, M., Wu, X., & Liu, X. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867053363153 · Cited by 619 · cited 1×
“[38] screened a library of 16 chalcones, which are broadly known to have anticancer properties [39], to identify compounds for disrupting the MDM2-p53 interaction.”
BackgroundFunctions of the MDM2 oncoprotein
Freedman, D. A., Wu, L., & Levine, A. J. (1999) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s000180050273 · Cited by 577 · cited 1×
“In turn, MDM2 protein directly binds to p53 and inhibits the activity of p53 through multiple mechanisms: MDM2 (1) directly inhibits the transactivation function of p53, (2) exports p53 out of the nucleus, and (3) promotes proteosome-mediated degradation of p53 through its E3 ubiquitin ligase activity [13–15].”
BackgroundKemp, C. J., Donehower, L. A., Bradley, A., & Balmain, A. (1993) · Cell · doi:10.1016/0092-8674(93)90461-x · Cited by 457 · cited 1×
“As with the human inherited cancer predisposition Li-Fraumeni syndrome, mice lacking p53 develop normally, but are predisposed to develop a variety of tumors [28].”
BackgroundDiscovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells
Grasberger, B. L., Lu, T., Schubert, C., Parks, D. J., Carver, T. E., Koblish, H. K., Cummings, M. D., LaFrance, L. V., Milkiewicz, K. L., Calvo, R. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049137g · Cited by 432 · cited 1×
“Benzodiazepinedione-based MDM2 inhibitors were discovered in a high throughput screening of 338,000 compounds from combinatorial libraries using ThermoFluor microcalorimetry technology [34].”
MethodMDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
Kojima, K., Konopleva, M., Samudio, I. J., Shikami, M., Cabreira-Hansen, M., McQueen, T., Ruvolo, V., Tsao, T., Zeng, Z., Vassilev, L. T., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0553 · Cited by 407 · cited 9×
“For example, ex vivo experiments using patient tumor samples have shown that Nutlin-3 synergizes with doxorubicin, chlorambucil, and fludarabine in B-CLL [85–87]; with doxorubicin and cytosine arabinoside in AML [88, 89]; and with doxorubicin in Hodgkin and Reed-Sternberg (HRS) cells [90].”
BackgroundInfluentialNUMB controls p53 tumour suppressor activity
Colaluca, I. N., Tosoni, D., Nuciforo, P., Senic-Matuglia, F., Galimberti, V., Viale, G., Pece, S., & Di Fiore, P. P. (2008) · Nature · doi:10.1038/nature06412 · Cited by 385 · cited 1×
“In addition to p53, MDM2 also binds to other proteins such as p73, E2F-1, HIF-1a, and Numb [78–81] using the same binding site.”
BackgroundOrner, B. P., Ernst, J. T., & Hamilton, A. D. (2001) · Journal of the American Chemical Society · doi:10.1021/ja0025548 · Cited by 320 · cited 1×
“Terphenyl compounds have been put forward as bearing a scaffold capable of mimicking one face of a-helical peptides [36].”
BackgroundMDM2 is a Central Node in the p53 Pathway: 12 Years and Counting
Bond, G., Hu, W., & Levine, A. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332627 · Cited by 308 · cited 2×
“For example, overexpression of MDM2 provides cells a growth advantage, promotes tumorigenesis, and correlates with a worse clinical prognosis and poor response to cancer therapy [18–24].”
BackgroundRegulation and Significance of Apoptosis in the Stem Cells of the Gastrointestinal Epithelium
Potten, C. S., Wilson, J. W., & Booth, C. (1997) · STEM CELLS · doi:10.1002/stem.150082 · Cited by 287 · cited 1×
“apoptosis [71, 72].”
Picksley, S. M., Vojtĕsek, B., Sparks, A., & Lane, D. P. (1994) · PubMed · Cited by 283
Chalcone Derivatives Antagonize Interactions between the Human Oncoprotein MDM2 and p53
Stoll, R., Renner, C., Hansen, S., Palme, S., Klein, C., Belling, A., Zeslawski, W., Kamionka, M., Rehm, T., Mühlhahn, P., et al. (2001) · Biochemistry · doi:10.1021/bi000930v · Cited by 275 · cited 1×
“[38] screened a library of 16 chalcones, which are broadly known to have anticancer properties [39], to identify compounds for disrupting the MDM2-p53 interaction.”
BackgroundRayburn, E., Zhang, R., He, J., & Wang, H. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332636 · Cited by 265 · cited 1×
“For example, overexpression of MDM2 provides cells a growth advantage, promotes tumorigenesis, and correlates with a worse clinical prognosis and poor response to cancer therapy [18–24].”
BackgroundInhibition of tumor angiogenesis by p53: a new role for the guardian of the genome
Teodoro, J. G., Evans, S. K., & Green, M. R. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0221-2 · Cited by 260 · cited 2×
“An efficient synthetic method featuring a [1,3]-dipolar cycloaddition reaction as the key step was developed for the synthesis of the designed compound.”
BackgroundMethodMdm2 is critically and continuously required to suppress lethal p53 activity in vivo
Ringshausen, I., O'Shea, C. C., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.010 · Cited by 256 · cited 1×
“tissues and death of all animals within days [73], raising the possibility that MDM2 inhibitors could be highly toxic to some normal tissues through activation of p53.”
BackgroundTerphenyl‐Based Helical Mimetics That Disrupt the p53/HDM2 Interaction
Yin, H., Lee, G., Park, H. S., Payne, G. A., Rodriguez, J. M., Sebti, S. M., & Hamilton, A. D. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200462316 · Cited by 255 · cited 1×
“3) was found to bind to MDM2 with a Ki of 182 nM [37].”
BackgroundGarcía-Echeverría, C., Chène, P., Blommers, M. J. J., & Furet, P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990966p · Cited by 246 · cited 1×
“These efforts led to the discovery of peptidomimetics that bind to MDM2 with Kd values of 1 nM, 1,000-fold more potent than wild-type p53 peptides [32].”
BackgroundKojima, K., Konopleva, M., McQueen, T., O'Brien, S., Plunkett, W., & Andreeff, M. (2006) · Blood · doi:10.1182/blood-2005-12-5148 · Cited by 245 · cited 1×
“For example, ex vivo experiments using patient tumor samples have shown that Nutlin-3 synergizes with doxorubicin, chlorambucil, and fludarabine in B-CLL [85–87]; with doxorubicin and cytosine arabinoside in AML [88, 89]; and with doxorubicin in Hodgkin and Reed-Sternberg (HRS) cells [90].”
BackgroundMDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin
Hu, B., Gilkes, D. M., Farooqi, B., Sebti, S. M., & Chen, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c600147200 · Cited by 236 · cited 1×
“Indeed, ectopic expression of MDMX and/or its downregulation by RNAi show that MDMX attenuates the p53 activation by selective MDM2 inhibitors and reduces the cellular activity of MDM2 inhibitors [50, 66, 75, 76].”
BackgroundColl-Mulet, L., Iglesias-Serret, D., Santidrián, A. F., Cosialls, A. M., de Frias, M., Castaño, E., Campàs, C., Barragán, M., de Sevilla, A. F., Domingo, A., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3273 · Cited by 234 · cited 1×
“For example, ex vivo experiments using patient tumor samples have shown that Nutlin-3 synergizes with doxorubicin, chlorambucil, and fludarabine in B-CLL [85–87]; with doxorubicin and cytosine arabinoside in AML [88, 89]; and with doxorubicin in Hodgkin and Reed-Sternberg (HRS) cells [90].”
BackgroundPopowicz, G. M., Czarna, A., Wolf, S., Wang, K., Wang, W., Dömling, A., & Holak, T. A. (2010) · Cell Cycle · doi:10.4161/cc.9.6.10956 · Cited by 230 · cited 1×
“This compound is an analogue of MI-219, but differs in its stereochemistry [64].”
BackgroundActivation of p53 by MDM2 Antagonists Can Protect Proliferating Cells from Mitotic Inhibitors
Carvajal, D., Tovar, C., Yang, H., Vu, B. T., Heimbrook, D. C., & Vassilev, L. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3576 · Cited by 201 · cited 1×
“Extensive studies have shown that while MDM2 inhibitors induce cell cycle arrest in all tumor cells with wild-type p53, they induce apoptosis/cell-death only in some tumor cells harboring wild-type p53 [33, 50, 66, 84].”
BackgroundJuven-Gershon, T., & Oren, M. (1999) · Molecular Medicine · doi:10.1007/bf03402141 · Cited by 194 · cited 1×
“In turn, MDM2 protein directly binds to p53 and inhibits the activity of p53 through multiple mechanisms: MDM2 (1) directly inhibits the transactivation function of p53, (2) exports p53 out of the nucleus, and (3) promotes proteosome-mediated degradation of p53 through its E3 ubiquitin ligase activity [13–15].”
BackgroundLevels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3
Patton, J. T., Mayo, L. D., Singhi, A. D., Gudkov, A. V., Stark, G. R., & Jackson, M. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3832 · Cited by 189 · cited 10×
“Both cell-death induction and cell cycle arrest in tumor cells depend upon p53, since knockdown or knockout of p53 abrogates these cellular effects by Nutlin-3 and MI-219 [50, 66].”
BackgroundInfluentialComparative study of the p53-mdm2 and p53-MDMX interfaces
Böttger, V., Böttger, A., Garcia-Echeverria, C., Ramos, Y. F., van der Eb, A. J., Jochemsen, A. G., & Lane, D. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202281 · Cited by 189 · cited 1×
“But unlike MDM2, MDMX does not induce p53 degradation [74].”
BackgroundHDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function
Lau, L. M. S., Nugent, J. K., Zhao, X., & Irwin, M. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210707 · Cited by 182 · cited 1×
“Using in vitro cell line models, it has been shown that Nutlin-3 disrupts the interaction of MDM2 with p73 [78], E2F-1 [79] and HIF-1a [80].”
MethodPotent and orally active small-molecule inhibitors of the MDM2-p53 interaction
Yu, S., Qin, D., Shangary, S., Chen, J., Wang, G., Ding, K., McEachern, D., Qiu, S., Nikolovska-Coleska, Z., Miller, R., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901400z · Cited by 180 · cited 4×
“Potent and specific MDM2 inhibitors such as Nutlin-3 [33] and MI-219 [50, 51]”
BackgroundMethodInfluentialSelf-citationAmbrosini, G., Sambol, E. B., Carvajal, D., Vassilev, L. T., Singer, S., & Schwartz, G. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210136 · Cited by 163 · cited 3×
“Using in vitro cell line models, it has been shown that Nutlin-3 disrupts the interaction of MDM2 with p73 [78], E2F-1 [79] and HIF-1a [80].”
MethodDNA damage-induced MDMX degradation is mediated by MDM2
Kawai, H., Wiederschain, D., Kitao, H., Stuart, J., Tsai, K. K. C., & Yuan, Z.-M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308295200 · Cited by 163 · cited 1×
“Interestingly, in some cancer cell lines, MDM2 inhibitors can induce MDMX degradation, presumably mediated though p53-dependent up-regulation of MDM2 [50, 66, 76], which is known to ubiquitinate and degrade MDMX during DNA damage [77].”
BackgroundHdmx modulates the outcome of p53 activation in human tumor cells
Wade, M., Wong, E. T., Tang, M., Stommel, J. M., & Wahl, G. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605405200 · Cited by 163 · cited 2×
“Interestingly, in some cancer cell lines, MDM2 inhibitors can induce MDMX degradation, presumably mediated though p53-dependent up-regulation of MDM2 [50, 66, 76], which is known to ubiquitinate and degrade MDMX during DNA damage [77].”
BackgroundSecchiero, P., Barbarotto, E., Tiribelli, M., Zerbinati, C., di Iasio, M. G., Gonelli, A., Cavazzini, F., Campioni, D., Fanin, R., Cuneo, A., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4465 · Cited by 158 · cited 1×
“For example, ex vivo experiments using patient tumor samples have shown that Nutlin-3 synergizes with doxorubicin, chlorambucil, and fludarabine in B-CLL [85–87]; with doxorubicin and cytosine arabinoside in AML [88, 89]; and with doxorubicin in Hodgkin and Reed-Sternberg (HRS) cells [90].”
BackgroundHardcastle, I. R., Liu, J., Valeur, E., Watson, A., Ahmed, S. U., Blackburn, T. J., Bennaceur, K., Clegg, W., Drummond, C., Endicott, J. A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1011929 · Cited by 151 · cited 1×
“4) has an IC50 value of 170 nM [61].”
BackgroundAllen, J. G., Bourbeau, M. P., Wohlhieter, G. E., Bartberger, M. D., Michelsen, K., Hungate, R., Gadwood, R. C., Gaston, R. D., Evans, B., Mann, L. W., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900681h · Cited by 148
Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas
Sarek, G., Kurki, S., Enbäck, J., Iotzova, G., Haas, J., Laakkonen, P., Laiho, M., & Ojala, P. M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30945 · Cited by 142 · cited 2×
“Significantly, the antitumor activity of these potent MDM2 inhibitors is achieved at dose schedules which cause no visible signs of toxicity in the animals, as assessed by necropsy studies and body weight loss [33, 50, 65, 69].”
BackgroundMutational spectrum of p53 mutations in primary breast and ovarian tumors
Feki, A., & Irminger-Finger, I. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.07.002 · Cited by 139 · cited 1×
“Consistent with its role as a prominent tumor suppressor, p53 is functionally inactivated by mutation or deletion in nearly 50% of human cancers [8].”
BackgroundCzarna, A., Beck, B., Srivastava, S., Popowicz, G. M., Wolf, S., Huang, Y., Bista, M., Holak, T. A., & Dömling, A. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201001343 · Cited by 134
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
Aziz, M. H., Shen, H., & Maki, C. G. (2011) · Oncogene · doi:10.1038/onc.2011.185 · Cited by 131
Small Molecule Inhibitors of the MDM2-p53 Interaction Discovered by Ensemble-Based Receptor Models
Bowman, A. L., Nikolovska-Coleska, Z., Zhong, H., Wang, S., & Carlson, H. A. (2007) · Journal of the American Chemical Society · doi:10.1021/ja073687x · Cited by 126 · cited 1×
“Another computational search was performed using a pharmacophore model based on the crystal structure of MDM2 with incorporation of protein flexibility assessed using molecular dynamics simulation [47].”
MethodSelf-citationAntiangiogenic Activity of the MDM2 Antagonist Nutlin-3
Secchiero, P., Corallini, F., Gonelli, A., Dell’Eva, R., Vitale, M., Capitani, S., Albini, A., & Zauli, G. (2007) · Circulation Research · doi:10.1161/01.res.0000253975.76198.ff · Cited by 126 · cited 2×
“The in vitro and in vivo anti-angiogenic activity of MDM2 inhibitors has been demonstrated using Nutlin-3 [82].”
BackgroundMétay, C., Paillerets, B. B., Lefrère, I., Ronsin, M., Feunteun, J., Tursz, T., & Wiels, J. (1998) · Oncogene · doi:10.1038/sj.onc.1201702 · Cited by 123 · cited 1×
“amplification of the MDM2 gene, single nucleotide polymorphism at nucleotide 309 (SNP309) in its gene promoter, enhanced transcription, and increased translation account for MDM2 overproduction [18, 24–26].”
BackgroundMolecular cloning of a cDNA specific for the murine p53 cellular tumor antigen.
Oren, M., & Levine, A. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.1.56 · Cited by 120 · cited 1×
“The p53 protein was identified in 1979 [4–6], and its gene, called TP53, was cloned in 1983 [7].”
BackgroundLu, Y., Nikolovska-Coleska, Z., Fang, X., Gao, W., Shangary, S., Qiu, S., Qin, D., & Wang, S. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060023+ · Cited by 115
Self-citationSaddler, C., Ouillette, P., Kujawski, L., Shangary, S., Talpaz, M., Kaminski, M., Erba, H., Shedden, K., Wang, S., & Malek, S. N. (2008) · Blood · doi:10.1182/blood-2007-09-112698 · Cited by 96 · cited 1×
“In addition to human cancer cell lines, cell death induction by MI-63 and Nutlin-3 were extensively evaluated using purified primary human chronic lymphocytic leukemia (CLL) cells [67] and acute myelogenous leukemia (AML) cells [68] from patients.”
BackgroundSelf-citationDrakos, E., Thomaides, A., Medeiros, L. J., Li, J., Leventaki, V., Konopleva, M., Andreeff, M., & Rassidakis, G. Z. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2581 · Cited by 95 · cited 1×
“For example, ex vivo experiments using patient tumor samples have shown that Nutlin-3 synergizes with doxorubicin, chlorambucil, and fludarabine in B-CLL [85–87]; with doxorubicin and cytosine arabinoside in AML [88, 89]; and with doxorubicin in Hodgkin and Reed-Sternberg (HRS) cells [90].”
BackgroundZhou, M., Gu, L., Abshire, T. C., Homans, A., Billett, A. L., Yeager, A., & Findley, H. W. (2000) · Leukemia · doi:10.1038/sj.leu.2401619 · Cited by 95 · cited 1×
“For example, overexpression of MDM2 provides cells a growth advantage, promotes tumorigenesis, and correlates with a worse clinical prognosis and poor response to cancer therapy [18–24].”
BackgroundGalatin, P. S., & Abraham, D. J. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm034182u · Cited by 90 · cited 2×
“When evaluated in a p53 reporter gene assay, only a 20% increase in p53 transcriptional function after treatment with 100 mM of the compound was observed [40].”
BackgroundMethodLaRusch, G. A., Jackson, M. W., Dunbar, J. D., Warren, R. S., Donner, D. B., & Mayo, L. D. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2710 · Cited by 89 · cited 2×
“Using in vitro cell line models, it has been shown that Nutlin-3 disrupts the interaction of MDM2 with p73 [78], E2F-1 [79] and HIF-1a [80].”
BackgroundMethodLong, J., Parkin, B., Ouillette, P., Bixby, D., Shedden, K., Erba, H., Wang, S., & Malek, S. N. (2010) · Blood · doi:10.1182/blood-2010-01-261628 · Cited by 85 · cited 3×
“Detailed genetic analysis revealed that 80% of AML cells with wild-type p53 and FLT-3 internal tandem duplication (FLT-3/ITD) mutation are highly sensitive to apoptosis via MDM2 inhibitors [68].”
BackgroundMethodSelf-citationMDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis
Ganguli, G., Abecassis, J., & Wasylyk, B. (2000) · The EMBO Journal · doi:10.1093/emboj/19.19.5135 · Cited by 82 · cited 1×
“Genetic studies in mice have revealed that overexpression of MDM2 at an early stage of differentiation neutralizes p53 tumor suppressor function and predisposes mice to tumorigenesis [27].”
BackgroundSaha, M. N., Jiang, H., Jayakar, J., Reece, D., Branch, D. R., & Chang, H. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.11.11882 · Cited by 82 · cited 1×
“Combination of Nutlin-3 with velcade, a proteasome inhibitor approved for the treatment of multiple myeloma, showed a synergistic activity in multiple myeloma cells harboring wild-type p53 [91].”
BackgroundGuenther, T., Schneider‐Stock, R., Häckel, C., Kasper, H., Pross, M., Hackelsberger, A., Lippert, H., & Roessner, A. (2000) · Modern Pathology · doi:10.1038/modpathol.3880107 · Cited by 69 · cited 1×
“For example, overexpression of MDM2 provides cells a growth advantage, promotes tumorigenesis, and correlates with a worse clinical prognosis and poor response to cancer therapy [18–24].”
BackgroundStructure and Organization of Amplified DNA on Double Minutes Containing the mdm2 Oncogene
Fakharzadeh, S. S., Rosenblum-Vos, L., Murphy, M., Hoffman, E. K., & George, D. L. (1993) · Genomics · doi:10.1006/geno.1993.1058 · Cited by 66 · cited 1×
“MDM2 is an oncoprotein that was initially discovered by its overexpression in a spontaneously transformed mouse cell line [8–12].”
BackgroundSecchiero, P., Zerbinati, C., di Iasio, M. G., Melloni, E., Tiribelli, M., Grill, V., & Zauli, G. (2007) · Current Drug Metabolism · doi:10.2174/138920007780655432 · Cited by 63 · cited 9×
“For example, ex vivo experiments using patient tumor samples have shown that Nutlin-3 synergizes with doxorubicin, chlorambucil, and fludarabine in B-CLL [85–87]; with doxorubicin and cytosine arabinoside in AML [88, 89]; and with doxorubicin in Hodgkin and Reed-Sternberg (HRS) cells [90].”
BackgroundInfluentialSaha, M. N., Jiang, H., Mukai, A., & Chang, H. H. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0471 · Cited by 55
Andreeff, M., Kojima, K., Padmanabhan, S., Strair, R., Kirschbaum, M., Maslak, P., Hillmen, P., O'Brien, S., Samaniego, F., Borthakur, G., et al. (2010) · Blood · doi:10.1182/blood.v116.21.657.657 · Cited by 29
QSAR: Hydropathic analysis of inhibitors of the p53–mdm2 interaction
Galatin, P. S., & Abraham, D. J. (2001) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.1136 · Cited by 20 · cited 1×
“The hydropathic interactions (HINT) program was used to generate noncovalent interaction measurements between reported p53-based peptide inhibitors and MDM2, which led to the development of a pharmacophore model [41].”
MethodBinder, B. R. (2007) · Circulation Research · doi:10.1161/01.res.0000255897.84337.38 · Cited by 16 · cited 1×
“In addition to having a direct effect on tumor cells, MDM2 inhibitors may inhibit angiogenesis through activation of p53 in endothelial cells [82, 83].”
BackgroundRay-Coquard, I., Blay, J., Italiano, A., Cesne, A. L., Penel, N., Zhi, J., Beryozkina, A., Heil, F., Rueger, R., NICHOLS, G. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.10007b · Cited by 11 · cited 1×
“Preliminary clinical data indicated that RG7112 appears to be well tolerated in patients and shows initial evidence of clinical activity and a mechanism of action consistent with targeting of the MDM2-p53 interaction [93–95].”
BackgroundBeryozkina, A., NICHOLS, G. L., Reckner, M., Vassilev, L. T., Rueger, R., Jukofsky, L., Middleton, S., Andreeff, M., Padmanabhan, S., STRAIR, R. K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3039 · Cited by 9 · cited 1×
“Preliminary clinical data indicated that RG7112 appears to be well tolerated in patients and shows initial evidence of clinical activity and a mechanism of action consistent with targeting of the MDM2-p53 interaction [93–95].”
BackgroundWang, S., Sun, W., Yu, S., Zhao, Y., Kumar, S., McEachern, D., Liu, L., Bernard, D., Sun, D., Zou, P., et al. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-lb-204 · Cited by 3
Self-citationSmith, M. A., Kang, M. H., Reynolds, C. P., Lock, R. B., Carol, H., Gorlick, R. G., Kolb, E. A., Maris, J. M., Keir, S. T., Billups, C. A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-c103 · Cited by 1
Cited by
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719
Molecular Mechanisms of Apoptosis and Roles in Cancer Development and Treatment
Goldar, S., Khaniani, M. S., Derakhshan, S. M., & Baradaran, B. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.6.2129 · Cited by 606
“Some of these small molecule MDM2 inhibitors such as R7112 (Nutlin-3, analogues of cisimidazoline) and JNJ-26854165 (a tryptamine derivative) are currently under clinical assessment in phase I studies (Tabernero et al., 2011; Shaomeng Wang et al., 2012; Sosin et al., 2012).”
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595
The role of p53 in cancer drug resistance and targeted chemotherapy
Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2017) · Oncotarget · doi:10.18632/oncotarget.13475 · Cited by 587
“RITA achieved much lower IC50 values than PRIMA-1 [22].”
BackgroundInfluentialZhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462
Self-citation
Metadata
- Authors
- Wang, S., Zhao, Y., Bernard, D., Aguilar, A., & Kumar, S.
- Affiliations
- University of Michigan (US)
- Corresponding author
- Wang, Shaomeng
- Venue
- Topics in Medicinal Chemistry
- Publisher
- Springer Berlin Heidelberg
- Published
- 2012
- Pages
- 57-79
- ISSN
- 1862-2461 (ISSN-L)
- 1862-247X
- OpenAlex
- W40735305
- Cited by
- 72
- References
- 88
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 7 · 2017: 4 · 2016: 9 · 2015: 8 · 2014: 16 · 2013: 9
- FWCI
- 21.12
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Topics in medicinal chemistry (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- MDM2, p53, p53-MDM2 interaction, small molecule inhibitors, p53 activation, cancer therapeutics, protein-protein interaction inhibitors, drug design, clinical trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.